Recombinant monoclonal antibody to PDGF-R alpha. Olaratumab is a monoclonal antibody which is for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.
Host: Human
Isotype: IgG1 - kappa
Applications: IF, IP, Neut, FuncS, ELISA, FC, ICC
Figure 1 Olaratumab prevents ligand-induced phosphorylation of PDGFRa.
A–C, A-204 and HuO9 cells (A), which only express PDGFRa, G-402 and MG-63 cells (B), which express both PDGF receptors, or G-401 cells (C), which are PDGFRb positive, were treated with 1 mmol/L IgG or olaratumab for 15 minutes and then stimulated with individual PDGFs (5 nmol/L). Whole-cell lysates were probed for phosphorylation of PDGF receptors and downstream effectors AKT and ERK1/2.
Lowery, C. D., Blosser, W., Dowless, M., Knoche, S., Stephens, J., Li, H., ... & Guo, Q. (2018). Olaratumab exerts antitumor activity in preclinical models of pediatric bone and soft tissue tumors through inhibition of platelet-derived growth factor receptor α. Clinical Cancer Research, 24(4), 847-857.
Figure 2 Olaratumab reduces osteosarcoma and MRT cell invasion in vitro.
A–E, A-204 (A), HuO9 (B), G-402 (C), MG-63 (D), or G-401 cells (E) were evaluated for cell invasion using a simplified Boyden chamber assay. Cells were incubated with IgG or olaratumab; individual PDGFs (5 nmol/L each, with the exception of 25 nmol/L PDGF-DD) or FBS served as chemoattractants. After 48 hours, the number of invasive cells was quantified using a fluorescence-based method and normalized to the serum-free media (SFM) IgG control. Results are presented as the summary of duplicate (G-402) or triplicate experiments SEM. P values were calculated using the Student t test. Significance indicators: , P < 0.05, P < 0.001.
Lowery, C. D., Blosser, W., Dowless, M., Knoche, S., Stephens, J., Li, H., ... & Guo, Q. (2018). Olaratumab exerts antitumor activity in preclinical models of pediatric bone and soft tissue tumors through inhibition of platelet-derived growth factor receptor α. Clinical Cancer Research, 24(4), 847-857.
Figure 3 Olaratumab inhibits tumor growth in A-204 and HuO9 cell line–derived xenograft mouse models.
A and B, Mice with A-204 subcutaneous xenografts were treated with either 40 mg/kg IgG control or 40 mg/kg olaratumab three times weekly for 4 weeks. A, Average tumor volume SEM (n ¼ 11/group) during the treatment period is shown. B, Waterfall plot of %Dtumor/control or %regression for individual animals at day 30. One animal in the treatment arm was found dead on day 17 and was not included in downstream analysis. C and D, Mice bearing HuO9 subcutaneous xenografts were treated with olaratumab (60 mg/kg)/1E10 (20 mg/kg) twice weekly and/or cisplatin or doxorubicin (5 mg/kg) once weekly. Treatment began at day 44 (dotted line) and continued for 5 weeks. C, A single HuO9 in vivo experiment is displayed in two separate graphs with the same control and olaratumab/1E10 arms but different chemotherapy-containing arms containing chemotherapy (left, cisplatin; right, doxorubicin). The graph displays average tumor volume SEM (n ¼ 6/group). D, Waterfall plot of individual %Dtumor/control or %regression at day 60. P values for tumor growth curves are displayed in Supplementary Table S4. PD, progressive disease (>10% growth); SD, stable disease ( 50%–10% growth); PR, partial regression ( 50% and>14 mm3).
Lowery, C. D., Blosser, W., Dowless, M., Knoche, S., Stephens, J., Li, H., ... & Guo, Q. (2018). Olaratumab exerts antitumor activity in preclinical models of pediatric bone and soft tissue tumors through inhibition of platelet-derived growth factor receptor α. Clinical Cancer Research, 24(4), 847-857.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-PDGFRA ADCC Recombinant Antibody (Olaratumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to PDGF-R alpha. Olaratumab is a monoclonal antibody which is for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.
CAT | Product Name | Application | Type |
TAB-878 | Anti-Human CD140a Recombinant Antibody (Tovetumab) | ELISA, FC, IP, FuncS, IF, Neut, WB | IgG2 - kappa |
TAB-1063CL | Human Anti-PDGFRA Recombinant Antibody (TAB-1063CL) | FuncS | Human antibody |
TAB-1063CL-S(P) | Human Anti-PDGFRA Recombinant Antibody; scFv Fragment (TAB-1063CL-S(P)) | ELISA | Human scFv |
TAB-1063CL-F(E) | Human Anti-PDGFRA Recombinant Antibody; Fab Fragment (TAB-1063CL-F(E)) | ELISA | Human Fab |
CAT | Product Name | Application | Type |
MOB-1274CT | Recombinant Mouse anti-Human PDGFRA Monoclonal antibody (27B2) | FC, ICC | |
HPAB-0232LY | Human Anti-PDGFRA Recombinant Antibody (clone 2.175.3) | Inhib, FC | Human IgG1 |
HPAB-0233LY | Human Anti-PDGFRA Recombinant Antibody (clone 2.451.1.1) | Inhib, FC | Human IgG1 |
HPAB-0234LY | Human Anti-PDGFRA Recombinant Antibody (clone 2.449.1.3) | Inhib, FC | Human IgG1 |
HPAB-0235LY | Human Anti-PDGFRA Recombinant Antibody (clone 2.998.2) | Inhib, FC | Human IgG1 |
CAT | Product Name | Application | Type |
NEUT-1848CQ | Recombinant Rat Anti-Pdgfra Antibody (APA5) | FC, FuncS, IHC-Fr, Neut, WB | IgG2a, κ |
NEUT-1849CQ | Recombinant Mouse Anti-PDGFRA Antibody (CBL458) | WB, IHC, Neut | IgG1 |
CAT | Product Name | Application | Type |
MOR-2637 | Hi-Affi™ Recombinant Rabbit Anti-PDGFRA Monoclonal Antibody (DS2637AB) | WB | IgG |
MOR-4662 | Hi-Affi™ Recombinant Rabbit Anti-PDGFRA Monoclonal Antibody (TH176DS) | WB, IF, ICC, ChIP | IgG |
CAT | Product Name | Application | Type |
HPAB-0232LY-S(P) | Human Anti-PDGFRA Recombinant Antibody (clone 2.175.3); scfv Fragment | Inhib, FC | Human scfv |
HPAB-0233LY-S(P) | Human Anti-PDGFRA Recombinant Antibody (clone 2.451.1.1); scfv Fragment | Inhib, FC | Human scfv |
HPAB-0234LY-S(P) | Human Anti-PDGFRA Recombinant Antibody (clone 2.449.1.3); scfv Fragment | Inhib, FC | Human scfv |
HPAB-0235LY-S(P) | Human Anti-PDGFRA Recombinant Antibody (clone 2.998.2); scfv Fragment | Inhib, FC | Human scfv |
HPAB-0236LY-S(P) | Human Anti-PDGFRA Recombinant Antibody (clone 2.84.3); scfv Fragment | Inhib, FC | Human scfv |
CAT | Product Name | Application | Type |
HPAB-0232LY-F(E) | Human Anti-PDGFRA Recombinant Antibody (clone 2.175.3); Fab Fragment | Inhib, FC | Human Fab |
HPAB-0233LY-F(E) | Human Anti-PDGFRA Recombinant Antibody (clone 2.451.1.1); Fab Fragment | Inhib, FC | Human Fab |
HPAB-0234LY-F(E) | Human Anti-PDGFRA Recombinant Antibody (clone 2.449.1.3); Fab Fragment | Inhib, FC | Human Fab |
HPAB-0235LY-F(E) | Human Anti-PDGFRA Recombinant Antibody (clone 2.998.2); Fab Fragment | Inhib, FC | Human Fab |
HPAB-0236LY-F(E) | Human Anti-PDGFRA Recombinant Antibody (clone 2.84.3); Fab Fragment | Inhib, FC | Human Fab |
CAT | Product Name | Application | Type |
AFC-TAB-192 | Afuco™ Anti-PDGFRA ADCC Recombinant Antibody (Olaratumab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-878 | Afuco™ Anti-PDGFRA ADCC Recombinant Antibody (Tovetumab), ADCC Enhanced | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
Submit a review or a question
There are currently no Customer reviews or questions for TAB-192. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.